Tilvestamab

立即咨询

Tilvestamab

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

2226775-26-2

BGB149

Tilvestamab (BGB149) 是一种人源化抗AXL抗体，阻断AXL介导的细胞信号传导。Tilvestamab 在体外能显著抑制Gas6刺激诱导的AXL激活，并抑制 786-0-Luc RCC 细胞中下游AXL的磷酸化。Tilvestamab可用于癌症，尤其是AXL过度表达肾细胞癌的研究。

生物活性

Tilvestamab (BGB149) is a humanized anti-AXLantibody that blocksAXL-mediated cell signaling. Tilvestamab significantly inhibitsGas6-inducedAXLactivation in 786-0-Luc RCC cells and inhibits downstreamAKTphosphorylation. Tilvestamab can be used incancerresearch, particularly inAXLoverexpressing renal cell carcinomas^[1].

IC₅₀& Target

AXL^[1].

体外研究
(In Vitro)

Tilvestamab (250 μM; 1 h) inhibits AXL phosphorylation in 786-0 cells^[1].

Cell Viability Assay^[1]

Cell Line:	786-0-Luc cells (Gas6- induced; Gas6 is a well characterized AXL ligand)
Concentration:	250 μM
Incubation Time:	1 h (pre-treat)
Result:	Drastically inhibited Gas6- induced AXL phosphorylation and decreased the level of pAKT.

体内研究
(In Vivo)

Tilvestamab (30 mg/kg; i.p.; twice a week) suppresses tumor growth by inhibiting AXL in orthotopic RCC model^[1].

Animal Model:	Female BALB/c athymic nude mice (8-week-old; orthotopic RCC model)^[1].
Dosage:	30 mg/kg
Administration:	Intraperitoneal injection; twice a week
Result:	Significantly inhibited RCC growth down to about 1/3 of the volume.

Clinical Trial

性状

Liquid

CAS 号

2226775-26-2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.